The global hydrocephalus shunts market size was valued at USD 456.13 million in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 3.99% from 2024 to 2030. The demand for hydrocephalus shunts is anticipated to upsurge owing to the advancements in the shunt technology, increase in the number of patients suffering from hydrocephalus and growing healthcare awareness. In addition, the rising geriatric population base is further expected to drive the demand for hydrocephalus shunts over the forecast period.
A variety of shunt configurations are available, such as lumbar-peritoneal (LP), ventriculoatrial (VA), and ventriculoperitoneal (VP) shunts. The type of shunt selected is determined by the unique requirements and health of the patient. These devices are made to stop over draining, which could result in complications. To sustain greater consistency in CSF pressure, these devices are included in certain shunt systems. For instance, in August 2023, in order to help patients with hydrocephalus disorders, Anuncia Medical Inc. launched the ReFlow Mini Flusher that would be available at a number of top neurosurgery centers in the U.S.. Using this device preventively could lower the high rate of shunt malfunctions brought on by catheter occlusions and lower the need for repeat revision brain surgery.
Increased awareness can result in early hydrocephalus diagnosis and treatment, which could drive up demand for shunts as more people need surgery. Better patient outcomes can result from increased knowledge since hydrocephalus can be recognized and treated faster. This may improve shunts' credibility as an effective therapeutic choice. A greater understanding may lead to more medical personnel receiving education and training in hydrocephalus shunt usage. By increasing the number of competent healthcare providers in the market, this might further boost industry growth. For instance, as per the data reported by Hydrocephalus Association the World Hydrocephalus Day was celebrated on 20th September 2023 in U.S., with the goal of bringing awareness about the hydrocephalus disorders and demonstrating support for people who are affected by this neurological disorder. The formally recognized annual awareness day received participation from several nations across the globe, including Israel, Great Britain, Australia, Canada, Nigeria, and Sweden.
Moreover, rising elderly population is one of the significant factors boosting the hydrocephalus shunts market over the forecast period. For instance, as per the reports of WHO, around 80% of elderly people by 2050 will reside in nations with a low or middle income. In addition, it is anticipated that the number of persons 80 years of age or older will be around 426 million by 2050.Therefore, with the constant increase in geriatric population, increase in the short- and long-term healthcare needs will drive the hydrocephalus shunts market growth at a global level.
The increasing prevalence of hydrocephalus is driving up demand for hydrocephalus shunts. The prevalence of hydrocephalus can rise due to genetic defects, neural tube defects resulting in brain and spinal cord abnormalities, tumors, and head injuries. Pregnancy-related exposure to specific substances or illnesses may raise the probability of an infant will have born with hydrocephalus. Improvements to lifestyle and food habits improve overall health and hence reduce the risk of conditions like hydrocephalus.
Several factors, including obesity, poor nutrition, and sedentary lifestyles, may contribute to health problems and increase the number of cases of hydrocephalus worldwide. For instance, as per the data published by National Library of Medicine in 2023, the global incidence of hydrocephalus by 2021 is estimated to be 85 per 100,000 people worldwide, with significant differences between age groups: 88 per 100,000 in children and 11 per 100,000 in adults.
The global hydrocephalus shunts market is characterized by the development of novel shunts employed to divert extra CSF from the brain to a different area of the body where it can be absorbed in the treatment of hydrocephalus. Reducing the size of shunt components and employing biocompatible materials to lower the possibility of negative reactions are the main goals of material and design advancements.
Several market players such as Aesculap, Inc., Medtronic, Integra LifeSciences are involved in receiving the regulatory approval for the novel product launch. Through such activities, these companies can expand their geographic reach and enter new territories.
For the medical device industry, regulations are crucial for ensuring the effectiveness and safety of devices. Medical device manufacturers are bound by stringent quality and safety regulations imposed by regulatory agencies like the European Medicines Agency and the U.S. FDA. In order for manufacturers to receive regulatory clearance for their hydrocephalus shunts, they must comply with certain guidelines.
The substitutes are available for hydrocephalus shunts which includes Endoscopic Third Ventriculostomy a surgical technique that makes a hole in the third ventricle's floor so that CSF may circulate through the obstruction. In a few instances, this can be used in place of shunt implantation.
Hospitals segment held the largest share in the hydrocephalus shunts market in 2023 and is expected to grow at the highest compound annual growth rate over the forecast period. Pediatric and neurosurgery-focused hospitals frequently have the facilities and expertise essential to recognize and manage hydrocephalus. Hospitals and shunt manufacturers may collaborate to provide training, support, and access to the latest technologies. Better patient outcomes and care can result from such kinds of collaborations Hospitals serve as the primary site for handling patients having hydrocephalus since they frequently have access to cutting-edge medical technology and a staff of trained healthcare specialists. Hospitals can undertake surgical procedures such as Ventriculoperitoneal Shunt, Ventriculoatrial Shunt and Lumboperitoneal Shunt placement surgeries.
For instance, according to Athar Institute of Health Management & Studies, the hospitals in India make up to 80% of the total healthcare market. Moreover, as per The Canadian Encyclopedia, there are 706 public & 193 private hospitals in Canada. Additionally, there has been an increase in medical tourism globally. Increase in medical tourism is expected to increase the quality of healthcare facilities provided by the hospitals. Thus, subsequent increase in number of patients across the globe, launch of technologically advanced products, and favorable reimbursement policies are leading to a growing demand for hospital applications. The rising awareness about availability & advantages of advanced medical facilities available at the hospitals is expected to help this segment grow over the forecast period.
North America dominated the overall hydrocephalus shunts regional market in 2023. This is attributed to the factors such as owing to the presence of key manufacturers such as Medtronic, Integra LifeSciences, Aesculap, Inc. also positively influencing the regional growth. Furthermore, rising prevalence of neurological disorders, increasing patient preference for minimal invasive procedures, increasing healthcare expenditure, improving R&D activities for the improvement in shunt technology are the factors contributing to the growth of the hydrocephalus shunts market in the North America. For instance, the Centers for Medicare & Medicaid Services (CMS) estimated that health spending was 7.5% in the U.S. in 2022. In 2023, it is anticipated that spending will reach USD 1 trillion for the first time. As Baby Boomers stop enrolling and sequester cutbacks continue to deepen, the growth of Medicare spending is anticipated to drop to 4.3% by 2030. In addition, high disposable income in developed economies & skilled professionals is some factors responsible for the large share of the market of the region.
U.S. accounted for the largest share of the hydrocephalus shunts market in North America in 2023. Growing incidence of hydrocephalus, and growing awareness regarding early disease diagnosis are some of the major factors anticipated to foster the country’s growth. Hydrocephalus can result from conditions that disrupt the neural tube during fetal development, such as spina bifida. The proper development of the brain and spinal cord may be impaired by these disorders. For instance, as per the data published by UCLA Health Hospitals stated that in the U.S., two infants out of every 1,000 are born with hydrocephalus. The number of persons who develop it after birth is unknown. Cerebrospinal fluid (CSF) shunts affect about 125,000 people, and 33,000 shunts are implanted in the U.S. each year.
Europe held a significant market share in 2023. A greater extent of public funding in Europe’s healthcare system has contributed to this growth. Market dynamics can be influenced by reimbursement policies and regulatory frameworks in European countries. Medical device safety and efficacy are ensured in large part by regulatory agencies such as the European Medicines Agency (EMA). Moreover, the healthcare systems in European nations are usually well-established and emphasize medical technology research and development. Adherence to regulatory norms is crucial for manufacturers seeking to penetrate or practice business in the European market.
Asia Pacific is expected to grow at a highest CAGR over the forecast period. Increasing awareness among consumers is expected to boost demand for hydrocephalus shunts and accessories in this region. Moreover, improving healthcare infrastructure, increasing medical surgeries, along with the government agreements for enhancing the medical device portfolio has a positive impact on the regional growth. For instance, in March 2022, USD 42 billion investment and five-year financial plan in India, was approved by the prime ministers of India and Japan, for a collaborative effort between both countries in the production of medical devices. Thus, driving the growth of the hydrocephalus shunts market in India.
India’s healthcare system is witnessing a transition in service portfolio from nursing care to preventive care in disease management because of rising healthcare expenditure. In addition, rising government initiatives for better healthcare infrastructure, and benefits associated with treatment of neurological disorders in the country are among the factors expected to propel market growth. China is the fastest-growing country in Asia Pacific due to increasing chronic disorder cases and growing preference for safe & effective neurological procedures, which is expected to boost the market growth.
Based on product, the hydrocephalus shunts market is segmented into valves, and catheters. In 2023, valves segment dominated the hydrocephalus shunts with the market share of around 71.26%. An essential part of hydrocephalus shunt systems are valves. They manage the CSF flow in the shunt system to keep the intracranial pressure at the appropriate level. Pressure valves are available in a variety of designs, such as fixed, programmed, and adjustable models, which enable medical practitioners to customize treatment to the individual needs of each patient.
Additionally, shunt systems with programmable valves facilitate adjustments without the need for invasive procedures. This reduces the necessity for additional surgeries and major invasive surgeries. For instance, the article published by National Library of Medicine in 2022 stated the use of hydrogel check valves for hydrocephalic fluid retention treatment using avea wireless fully passive sensor for intracranial pressure monitoring. As an alternative to hydrocephalus treatment, the hydrogel check valve demonstrated almost identical flow features, with little or no reverse flow leakage over zero cracking pressure.
Whereas catheters segment is expected to grow at a highest CAGR over the forecast period. Shunt infections are more common in some patient populations, and catheters are an essential part of hydrocephalus management. To lower the danger of infection or tissue irritation, shunt catheters are often manufactured from biocompatible materials. Cerebrospinal fluid (CSF) is diverted by catheters to a point inside the body where it will be absorbed instead of the site where there is an excess volume of CSF. The catheters help to reduce intracranial pressure caused due to hydrocephalus in the brain.
zAdditionally, hydrocephalus symptoms, including nausea, headaches, and neurological disorders, can be prevented, or reduced with the use of catheters in the shunts. Thus, the abovementioned factors are anticipated to augment the overall segment growth. For instance, as per the data published by National Library of Medicine in 2022, in an in vitro model of hydrocephalus, polyvinylpyrrolidone-coated catheters reduced the astrocyte adhesion and enhance flow/pressure performance.
Medtronic has a global presence and operates from over 370 locations in approximately 160 countries.
IntegraLifeSciences is dedicated to developing products related to human health and well-being. The product portfolio includes array of products and services for the treatment of various conditions, such as hemorrhagic stroke, hydrocephalus, brain tumors, and traumatic brain injuries.
Sophysa operates in 70 countries across the UK, Asia, and Europe, and supplies medical devices to various end users, such as hospitals.
Hpbio is involved in the creation and production of devices for surgical and implant operations. Its primary area of expertise is in the production of silicone products, including drainage systems and catheters.
In November 2023, for young patients suffering from hydrocephalus-a neurological disorder that results in an accumulation of cerebral fluid in the interior spaces of the brain which often requires repeated hospital stays-surgeons at Intermountain Primary Children's Hospital successfully placed a novel brain shunt accessory, becoming the first hospital in the U.S. to accomplish the same.
In October 2023, through its Blueprint MedTech initiative, the NINDS (National Institute of Neurological Disorders and Stroke) of the National Institutes of Health (NIH) awarded Rhaeos, Inc. a USD 1.5 million grant. With this award, the company will continue to develop its FDA-designated breakthrough medical technology, which aims to revolutionize the treatment of hydrocephalus, a brain disorder that affects more than a million people in the U.S.
In August 2023, registration for the handheld MRI system-based HOPE PMR Pediatric Hydrocephalus study was completed. The observational multi-site study intended to alter the standard procedure to treat pediatric hydrocephalus with the Swoop system, a brain imaging device that can be used in outpatient, inpatient, and emergency pediatric care settings. This can be accessed at the child's bedside and emits no ionizing radiation. The portable MRI system was developed by Hyperfine, Inc.
In January 2022, the Adult Hydrocephalus Clinical Research Network selected the Emory Brain Health Center to participate part in a study on the efficacy of shunt therapy for iNPH (idiopathic normal pressure hydrocephalus). Funded by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, USD 14 million multi-site program was the largest ever awarded to study adult hydrocephalus.
Market size value in 2024
USD 474.01 million
Revenue forecast in 2030
USD 599.42 million
CAGR of 3.99% from 2024 to 2030
Base year for estimation
2018 - 2022
2024 - 2030
Revenue in USD million and CAGR from 2024 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, end-use, region
North America, Europe, Asia Pacific, Latin America, MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Medtronic; Aesculap, Inc.; Spiegelberg GmbH & Co. KG.; Integra LifeSciences; Sophysa; CHRISTOPH MIETHKE GMBH & CO. KG; Hpbio; G. Surgiwear Ltd; Bicakcilar
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global hydrocephalus shunts market report on the basis of product, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Ambulatory Surgical Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global hydrocephalus shunts market size was estimated at USD 456.13 million in 2023 and is expected to reach USD 474.01 million in 2024.
b. The global hydrocephalus shunts market is expected to grow at a compound annual growth rate of 3.99% from 2024 to 2030 to reach USD 599.42 million by 2030.
b. The valves segment held the largest market share of 71.26% in 2023 and is anticipated to grow with the fastest CAGR of 3.68% during the forecast period. Technological advances, new product approvals, and increasing prevalence of neurological disorders are factors driving the market.
b. Some key players in the market are Medtronic; Aesculap, Inc.; Spiegelberg GmbH & Co. KG.; Integra LifeSciences; Sophysa; B. Braun SE; CHRISTOPH MIETHKE GMBH & CO. KG; Hpbio; G. Surgiwear Ltd; Bicakcilar, and others.
b. The demand for hydrocephalus shunts is anticipated to upsurge owing to the advancements in shunt technology, increase in the number of patients suffering from hydrocephalus, and growing healthcare awareness. In addition, the rising geriatric population base is further expected to drive the demand for hydrocephalus shunts over the forecast period.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."